Equity · Energy
CLB
NYSECore Laboratories Inc. /DE/ (CLB)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for CLB to draw a line in its place.
- Market cap
- 467.6M USD
- P/E (TTM)
- 30.0
- Revenue, year to Dec 2025
- 526.5M USD
- EPS, diluted, year to Dec 2025
- 0.63 USD
- 52-week range
- 9 USD – 20 USD
- Avg volume
- 42.1K
as of Nov 2, 2026
Have Core Laboratories Inc. /DE/ (CLB) insiders bought or sold shares recently?
CLB has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 1 October 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 31 Jul 2026 | Bruno LawrenceChairman and CEO | Buy | 5,000 | 54K USD |
30 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Tattoli Mark DamianSVP, Gen Counsel & Secretary | Tax withheld | 276 | 3K USD |
| 01 Oct 2026 | Tattoli Mark DamianSVP, Gen Counsel & Secretary | Option exercise | 700 | |
| 01 Oct 2026 | Teo Sow HangCAO & Treasurer | Tax withheld | 99 | 966 USD |
| 01 Oct 2026 | Teo Sow HangCAO & Treasurer | Option exercise | 250 | |
| 01 Aug 2026 | Teo Sow HangCAO & Treasurer | Tax withheld | 198 | 2K USD |
| 01 Aug 2026 | Teo Sow HangCAO & Treasurer | Option exercise | 440 | |
| 01 Aug 2026 | Tattoli Mark DamianSVP, Gen Counsel & Secretary | Tax withheld | 99 | 1K USD |
| 01 Aug 2026 | Tattoli Mark DamianSVP, Gen Counsel & Secretary | Option exercise | 250 | |
| 01 May 2026 | Tattoli Mark DamianSVP, Gen Counsel & Secretary | Tax withheld | 97 | 1K USD |
| 01 May 2026 | Tattoli Mark DamianSVP, Gen Counsel & Secretary | Option exercise | 250 | |
| 01 Apr 2026 | Murray KatherineDirector | Option exercise | 8,069 | |
| 01 Apr 2026 | ANASTASIO CURTDirector | Option exercise | 8,069 |
Showing the 12 most recent of 30 compensation filings in this window. The figures above count all of them.
Which funds hold Core Laboratories Inc. /DE/ (CLB)?
5 of the 45 institutional funds we track reported a Core Laboratories Inc. /DE/ position for the quarter ended 30 Jun 2026 — a combined 13.4M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Trimmed | 447,949 | 5.2M USD | −39.2% |
| Citadel Advisors | Added | 371,615 | 4.3M USD | +140.1% |
| D. E. Shaw & Co. | Added | 248,070 | 2.9M USD | +109.5% |
| AQR Capital Management | Held (±25%) | 64,809 | 755K USD | +24.8% |
| Renaissance Technologies | Trimmed | 14,500 | 169K USD | −71.3% |
| Marshall Wace | Exited | |||
| Millennium Management | Exited |
What has been filed or recorded for Core Laboratories Inc. /DE/ (CLB)?
The filings we hold for Core Laboratories Inc. /DE/, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.12 USD | Revenue $132M |
| 30 Sep 2026 | Financials | Total assets | 593.5M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 278.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.13 USD | Revenue $125M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.02 USD | Revenue $122M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.63 USD | Revenue $527M |
| 31 Dec 2025 | Financials | Revenue | 526.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 29.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.63 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.30 USD | Revenue $135M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.22 USD | Revenue $130M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.00 USD | Revenue $124M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 0.66 USD | Revenue $524M |
Core Laboratories Inc. /DE/ (CLB): frequently asked questions
What is Core Laboratories Inc. /DE/’s market cap?
Core Laboratories Inc. /DE/ is worth 467.6M USD by market value as of 2 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Core Laboratories Inc. /DE/’s P/E ratio?
Core Laboratories Inc. /DE/ has a price-to-earnings ratio of 30.0, as of 2 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Core Laboratories Inc. /DE/’s revenue?
Core Laboratories Inc. /DE/ reported revenue of 526.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Core Laboratories Inc. /DE/ insiders bought or sold shares recently?
No Core Laboratories Inc. /DE/ insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 1 Oct 2026 (SEC Form 4). See Insiders
Which funds own Core Laboratories Inc. /DE/?
5 of the 45 funds we track reported a Core Laboratories Inc. /DE/ position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Fisher Asset Management, Citadel Advisors and D. E. Shaw & Co. See Funds
When did Core Laboratories Inc. /DE/ last report earnings?
Core Laboratories Inc. /DE/ last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.12 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings